Pular para o conteúdo principal
Ranking Invest

STOK - Stoke Therapeutics, Inc.

Segmento: HealthcareStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Análise Ranking Invest

Valuation estimado
$ 29.19 Mi
Valor de Mercado
$ 1.87 Bi
Sobrepreço (AV)+6317.7%
IVR
0.02A companhia vale 0,02 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.17O valuation alternativo equivale a -17% do valor de mercado da companhia.
MLL
-0.17O lucro líquido dos controladores em 16 trimestres equivale a -17% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 345.55 Mi

Dívida Líquida

-$ 110.00 Mi

L4T

-$ 207.90 Mi

MM4T

-1489.11%

Indicadores Básicos

ROE

-60.17%

Índices de Previsibilidade

Receita Líquida

F0.58

Lucro

B0.25

Margem

D0.94

Índices de Tendência

Receita Líquida

C5.72

Lucro

G-8.69

Margem

D-0.34

Índices de Endividamento

DIV/PAT

-0.32

DIV/L4T

0.53

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.